R(h)oads to microvesicles

Small GTPases

Volumn 3, Issue 4, 2012, Pages

  Antonyak, Marc A ^a   Wilson, Kristin F ^a   Cerione, Richard A ^a  

^a Department of Obstetrics Gynecology   (United States)

Author keywords

Cancer; Cell communication; Glutaminase; GTPase; Microvesicles; Oncosomes; Rho; Tissue trans glutaminase; Transformation; Warburg effect

Indexed keywords

EPIDERMAL GROWTH FACTOR; FIBRONECTIN; GUANOSINE TRIPHOSPHATASE; PROTEIN CDC42; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; RAC PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

BIOGENESIS; CANCER CELL; CANCER GROWTH; CELL COMMUNICATION; CELL MEMBRANE; CELL METABOLISM; CELL TRANSFER; CELL TRANSFORMATION; HUMAN; MICROVESICLE; NONHUMAN; NOTE; PARACRINE SIGNALING; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION;

EID: 84870234316     PISSN: 21541248     EISSN: 21541256     Source Type: Journal    
DOI: 10.4161/sgtp.20755     Document Type: Note

References (30)

1. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, et al. Intercellular transfer of the onco-genic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol 2008; 10:619-24; PMID: 18425114; http://dx.doi.org/10.1038/ ncb 1725.
2. Antonyak MA, Li B, Boroughs LK, Johnson JL, Druso JE, Bryant KL, et al. Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells. Proc Natl Acad Sci USA 2011; 108:4852-7; PMID: 21368175; http://dx.doi.org/10.1073/ pnas. 1017667108.
3. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008; 10:1470-6; PMID:19011622; http:// dx.doi.org/10.1038/ncb1800.
4. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 2011; 21:139-46; PMID:21251983; http://dx.doi. org/10.1016/j.semcancer.2011.01.002.
5. Schauer IG, Sood AK, Mok S, Liu J. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia 2011; 13:393-405; PMID:21532880.
6. Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. J Cell Physiol 2009; 218:460-6; PMID:19006176; http://dx.doi. org/10.1002/jcp.21635.
7. Eccles SA. The epidermal growth factor recep-tor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol 2011; 55:685-96; PMID:22161825; http://dx.doi.org/10.1387/ ijdb.113396se.
8. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33:369-85; PMID:16890793; http://dx.doi. org/10.1053/j.seminoncol.2006.04.003.
9. Moscatello DK, Montgomery RB, Sundareshan P, McDanel H, Wong MY, Wong AJ. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 1996; 13:85-96; PMID:8700557
10. Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol 2009; 19:43-51; PMID:19144520; http://dx.doi. org/10.1016/j.tcb.2008.11.003.
11. Muralidharan-Chari V, Clancy JW, Sedgwick A, D'Souza-Schorey C. Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci 2010; 123:1603-11; PMID:20445011; http://dx.doi.org/10.1242/jcs.064386.
12. Li B, Antonyak MA, Zhang J, Cerione RA. RhoA triggers a specific signaling pathway that generates transforming microvesicles in cancer cells. Oncogene 2012; In press; PMID:22266864; http://dx.doi. org/10.1038/onc.2011.636.
13. Folk JE. Transglutaminases. Annu Rev Biochem 1980; 49:517-31; PMID:6105840; http://dx.doi. org/10.1 146/annurev.bi.49.07018 0.0 02505.
14. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA, et al. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 2008; 68:5849-58; PMID:18632639; http://dx.doi.org/10.1158/0008-5472.CAN-07-6130.
15. Li B, Antonyak MA, Druso JE, Cheng L, Nikitin AY, Cerione RA. EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation. Proc Natl Acad Sci USA 2010; 107:1408-13; PMID:20080707; http://dx.doi. org/10.1073/pnas. 0907907107.
16. Yuan L, Siegel M, Choi K, Khosla C, Miller CR, Jackson EN, et al. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 2007; 26:2563-73; PMID: 17099729; http://dx.doi.org/10.1038/ sj.onc.1210048.
17. Boroughs LK, Antonyak MA, Johnson JL, Cerione RA. A unique role for heat shock protein 70 and its binding partner tissue transglutaminase in cancer cell migration. J Biol Chem 2011; 286:37094-107; PMID:21896482; http://dx.doi.org/10.1074/jbc. M111.242438.
18. Nobes CD, Hall A. Rho, rac and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia and filopodia. Cell 1995; 81:53-62; PMID:7536630; http://dx.doi.org/1 0.1016/00 92-8674(95) 90370-4.
19. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000; 406:532-5; PMID:10952316; http://dx.doi.org/10.1038/35020106.
20. Sahai E, Ishizaki T, Narumiya S, Treisman R. Transformation mediated by RhoA requires activity of ROCK kinases. Curr Biol 1999; 9:136-45; PMID: 10021386; http://dx.doi.org/10.1016/S0960-9822(99)80067-0.
21. Hahmann C, Schroeter T Rho-kinase inhibitors as therapeutics: from pan inhibition to iso-form selectivity. Cell Mol Life Sci 2010; 67:171-7; PMID:19907920; http://dx.doi.org/10.1007/ s00018-009-0189-x.
22. Scott RW, Olson MF. LIM kinases: function, regulation and association with human disease. J Mol Med (Berl) 2007; 85:555-68; PMID:17294230; http:// dx.doi.org/10.1007/s00109-007-0165-6.
23. Erickson JW, Cerione RA. Glutaminase: a hot spot for regulation of cancer cell metabolism? Oncotarget 2010; 1:734-40; PMID:21234284.
24. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011; 11:325-37; PMID:21508971; http://dx.doi.org/10.1038/ nrc3038.
25. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010; 18:207-19; PMID:20832749; http://dx.doi.org/10.1016/j.ccr.2010.08.009.
26. Robinson MM, McBryant SJ, Tsukamoto T, Rojas C, Ferraris DV, Hamilton SK, et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide (BPTES). Biochem J 2007; 406:407-14; PMID:17581113; http://dx.doi.org/10.1042/ BJ20070039.
27. Ridley AJ. Life at the leading edge. Cell 2011; 145:1012-22; PMID: 21703446; http://dx.doi. org/10.1016/j.cell.2011.06.010.
28. Gadea G, de Toledo M, Anguille C, Roux P. Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices. J Cell Biol 2007; 178:23-30; PMID:17606864; http://dx.doi. org/10.1083/jcb.200701120.
29. Hart MJ, Eva A, Zangrilli D, Aaronson SA, Evans T, Cerione RA, et al. Cellular transformation and guanine nucleotide exchange activity are catalyzed by a common domain on the dbl oncogene product. J Biol Chem 1994; 269:62-5; PMID:8276860.
30. Hart MJ, Eva A, Evans T, Aaronson SA, Cerione RA. Catalysis of guanine nucleotide exchange on the CDC42Hs protein by the dbl oncogene product. Nature 1991; 354:311-4; PMID:1956381; http:// dx.doi.org/10.1038/354311a0.